2011
P2-02-09: TP53 Mutation Patterns in Breast Cancer Subgroups.
Dumay A, Feugeas J, Wittmer E, Lehmann-Che J, Bertheau P, Espié M, de C, André F, Sotiriou C, Pusztai L, de T. P2-02-09: TP53 Mutation Patterns in Breast Cancer Subgroups. Cancer Research 2011, 71: p2-02-09-p2-02-09. DOI: 10.1158/0008-5472.sabcs11-p2-02-09.Peer-Reviewed Original ResearchLuminal tumorsMolecular apocrineBreast cancerTP53 mutationsDifferent molecular subclassesLuminal B subgroupMolecular apocrine tumoursTruncating mutationsBreast cancer subgroupsBreast cancer subclassesTP53 mutation frequencyFunctional assaysMutation typeTP53 mutation patternsHigh rateTumor protein 53Missense mutationsApocrine tumorsBasal tumorsLuminal subgroupCancer subgroupsP53 gene inactivationMolecular subclassesBreast tumorsSpecific subtypes
2006
DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: Current data and issues on study design
Andre F, Mazouni C, Hortobagyi GN, Pusztai L. DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: Current data and issues on study design. Biochimica Et Biophysica Acta 2006, 1766: 197-204. PMID: 16962247, DOI: 10.1016/j.bbcan.2006.08.002.Peer-Reviewed Original ResearchConceptsStudy designPredictive biomarkersBreast cancer patientsPredictors of efficacyBreast cancer populationCase-control studySevere side effectsNeoadjuvant chemotherapyResistant patientsCancer patientsCancer populationBreast cancerSide effectsMolecular subclassesPredictive diagnostic toolGene signatureChemotherapyPatientsCancer pharmacogenomicsVariable benefitDiagnostic toolBiomarkersCurrent dataEfficacyPredictors